Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 11/2005

01.11.2005 | Educational Review

Germ Cell Tumors of the Testis

verfasst von: Brett S. Carver, MD, Joel Sheinfeld, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

Testicular cancer is the most common malignancy in men aged 20 to 35 years and accounts for approximately 1% of all male malignancies. Through the appropriate utilization of clinical trials, effective treatment paradigms have been developed for the management of all stages of testicular cancer. The multidisciplinary approach to the management of germ cell tumors of the testis has resulted in survival rates of > 90% overall. This review summarizes the principal management of germ cell tumors of the testis, highlighting the indications for surgery, controversies surrounding the integration of surgery, and alternative management strategies.
Literatur
1.
American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society, 2005
2.
Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170:5–11CrossRef
3.
McKiernan J, Goluboff E, Liberson G, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 1999;162:361–3CrossRef
4.
Daniels J, Stutzman R, McLeod D. A comparison of testicular tumors in black and white patients. J Urol 1981;125:341–2
5.
Bosl G, Bajorin D, Sheinfeld J, Motzer R, Chaganti R. Cancer of the testis. In: Devita Y, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 2000:1491–518
6.
Moul J, Paulson D, Dodge R, Walther P. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 1990;143:520–3
7.
Bosl G, Goldman A, Lange P, Vogelzang N, Fraley E, Levitt S. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981;2:970–3CrossRef
8.
Moul J, Moellman J. Unnecessary mastectomy for gynecomastia in a testicular cancer patient. Mil Med 1992;157:433–4
9.
Stephenson AJ, Russo P, Kaplinsky R, Sheinfeld J. Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. J Urol 2004;171:1474–7CrossRef
10.
Bochner BH, Lerner SP, Kawachi M, Williams RD, Scardino PT, Skinner DG. Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? Urology 1995;46:408–11CrossRef
11.
Capelouto C, Clark P, Ransil B, Loughlin K. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995;153:1397–401
12.
Van der Schyff S, Heidenreich A, Weifbach L. Organ preserving surgery in testicular cancer: long term results (abstract). J Urol 2000;163:645A
13.
Leibovitch I, Foster R, Kopecky K, Donohue J. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759–63CrossRef
14.
Hilton S, Herr H, Teitcher J, Begg C, Castellino R. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997;169:521–5
15.
Fleming I, ed. AJCC Cancer Staging Handbook. Philadelphia: Lippincott-Raven, 1998
16.
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594–603
17.
Jamieson J, Dobsin J. Lymphatics of the testicle. Lancet 1910;493–5. CrossRef
18.
Skinner D, Leadbetter W. The surgical management of testis tumors. J Urol 1971;106:84–93
19.
Donohue J, Zachary J, Maynard B. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128:315–20
20.
Weiscbach L, Boedefeld E. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as a basis for a modified staging lymph node dissection in stage I. J Urol 1987;138:77–82
21.
Sogani P. Evolution of the management of stage I nonseminomatous germ cell tumors of the testis. Urol Clin North Am 1991;18:561–73
22.
Fossa S, Horwich A, Russell J, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146–54
23.
Fossa S, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long term post irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383–8
24.
Dosmann M, Zagars G. Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 1993;26:382–90
25.
Willan B, McGowan D. Seminoma of the testis: a 22 year experience with radiotherapy. Int J Radiat Oncol Biol Phys 1985;11:1769–75
26.
Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–62
27.
von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931–4.
28.
Loehrer P, Birch R, Williams S, Greco A, Einhorn L. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987;5:1212–20
29.
Lashley D, Lowe B. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25:405–23CrossRef
30.
Pohar K, Rabbani F, Bosl G, Motzer R, Bajorin D, Sheinfeld J. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 2003;170:1155–8CrossRef
31.
Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855–8CrossRef
32.
Jewett M, Kong Y, Goldberg S, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988;139:1220–3
33.
Baniel J, Foster R, Rowland R, Bihrle R, Donohue J. Complications of primary retroperitoneal lymph node dissection. J Urol 1994;152:424–7
34.
Hartlapp J, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl 1987;10:277–84
35.
Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991;9:1393–6
36.
Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993;149:237–43
37.
Rabbani F, Sheinfeld J, Mohseni HF, Leon A, Rentzepis MJ, Reuter VE. Low volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:2020–5
38.
Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433–8
39.
Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464–7CrossRef
40.
Gerber GS, Bissada NK, Hulbert JC, Kavoussi LR, Moore RG, Kantoff PW. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J Urol 1994;152:1188–92
41.
Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J Urol 1996;156:1108–13CrossRef
42.
Janetschek G, Hobisch A, Holtl L, Bartsch G. Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve. J Urol 1996;156:89–93CrossRef
43.
Nelson JB, Chen RN, Bishoff JT, Oh WK, Kantoff PW, Donehower RC. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999;54:1064–7CrossRef
44.
LeBlanc E, Caty A, Dargent D, Querleu D, Mazeman E. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001;165:89–92CrossRef
45.
Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003;62:324–7CrossRef
46.
Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch G. Long-term result of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 2004;63:550–5CrossRef
47.
Castillo OA, Urena RD, Pinto IF. Laparoscopic retroperitoneal lymph node dissection for stage I, II NSGCT: 10 years experience (abstract). J Urol 2004;171:933A.
48.
Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37:251–60CrossRef
49.
Oliver RT, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 1992;148:1453–5
50.
Cullen M, Stenning S, Parkinson M. Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis (NSGCTT): an MRC (UK) study report (abstract). Proc Am Soc Clin Oncol 1995;14:244
51.
Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor. J Urol 2000;163:1785–7CrossRef
52.
Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725–32
53.
Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–23CrossRef
54.
Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23:2781–8CrossRef
55.
Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163–72
56.
Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988;6:1031–40
57.
Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692–701
58.
Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683–94
59.
Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177–87
60.
Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818–26
61.
Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569–73
62.
Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 1998;16:65–71
63.
Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275–80
64.
Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993;11:1294–9
65.
Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol 2001;19:2647–57
66.
Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176–9
67.
Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997;15:1455–64
68.
Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989;141:557–9
69.
Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998;159:133–8
70.
Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170–6
71.
Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol 1995;154:1370–2CrossRef
72.
Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43:74–80CrossRef
73.
Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11:324–9
74.
Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 2004;171:168–71CrossRef
75.
Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860–2CrossRef
76.
De Santis M, Becherer A, Bokemeyer C, et al. 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034–9CrossRef
77.
Moshorafa AA, Foster RS, Koch MO. Complications of post-chemotherapy retroperitoneal lymph node dissection (abstract). J Urol 2003;169:930A
78.
Patel MI, Beck S, Bosl GJ, Sheinfeld J. Histology of good risk nonseminomatous germ cell tumor (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after 4 cycles of etoposide and cisplatin (EPx4) (abstract). J Urol 2003;169:681A
79.
See WA, Laurenzo JF, Dreicer R, Hoffman HT. Incidence and management of testicular carcinoma metastatic to the neck. J Urol 1996;55:590–2CrossRef
80.
Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 1986;57:978–83
81.
Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified. Chest 1997;112:967–73
82.
Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996;14:1765–9
Metadaten
Titel
Germ Cell Tumors of the Testis
verfasst von
Brett S. Carver, MD
Joel Sheinfeld, MD
Publikationsdatum
01.11.2005
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2005
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.01.013

Weitere Artikel der Ausgabe 11/2005

Annals of Surgical Oncology 11/2005 Zur Ausgabe

Original Articles

Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect

Annual Heritage Presentation

Society of Surgical Oncology Heritage Award: Introduction—Honoring Samuel Alonzo Wells, Jr., MD

Original Articles

The Consequence of Multiple Re-Excisions to Obtain Clear Lumpectomy Margins in Breast Cancer Patients

Letters to the Editor

Multidisciplinary Sequential Therapy for the Treatment of Peritoneal Surface Malignancies of Colorectal Origin: A Plea for Cooperation Between Medical and Surgical Oncologists

Letters to the Editor

Hepatic Resection at a Major Community-Based Teaching Hospital Can Result in Good Outcome

Original Articles

Increased Expression of Valosin-Containing Protein (p97) Is Correlated With Disease Recurrence in Follicular Thyroid Cancer

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise